Loading...
Market
Number of major pharma companies investing in new cervical cancer treatment by end of 2024?
3
Resolution / Starting Odds
0-2 companies • 25%
3-5 companies • 25%
6-8 companies • 25%
More than 8 companies • 25%
Company press releases or major financial news outlets
Story
New Cervical Cancer Treatment Cuts Death Risk by 40%, Experts Call for NHS Rollout
Oct 15, 2024, 06:32 AM
Researchers have discovered that a simple change in the administration order of drugs for cervical cancer treatment can reduce the risk of death by 40%. This breakthrough, described as the biggest in two decades, has led experts to call for a full NHS rollout. The new regime, which has been supported by a study published in The Lancet, has the potential to transform survival rates for patients with cervical cancer.
View original story
Similar markets
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
Less than 20 countries • 25%
20 to 40 countries • 25%
41 to 60 countries • 25%
More than 60 countries • 25%
None • 25%
1-2 • 25%
3-4 • 25%
5 or more • 25%
0 companies • 25%
1-2 companies • 25%
3-4 companies • 25%
5 or more companies • 25%
None • 25%
1-2 companies • 25%
3-5 companies • 25%
More than 5 companies • 25%
No countries • 25%
1 to 5 countries • 25%
6 to 10 countries • 25%
More than 10 countries • 25%
Pfizer • 25%
AstraZeneca • 25%
Johnson & Johnson • 25%
No partnership • 25%
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
United States • 25%
United Kingdom • 25%
Germany • 25%
Other • 25%
Yes • 50%
No • 50%
Pfizer • 25%
Johnson & Johnson • 25%
AstraZeneca • 25%
Other • 25%